{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:55:33Z","timestamp":1790931333013,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00259-026-08039-2","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:13:30Z","timestamp":1783152810000},"page":"6944-6954","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-like peptide-1 receptor PET in indolent and aggressive insulinoma: Diagnostic performance, quantitative differences, and clinical implications"],"prefix":"10.1007","volume":"53","author":[{"given":"Junyan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-7522","authenticated-orcid":false,"given":"Shaoli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"8039_CR1","doi-asserted-by":"publisher","first-page":"897","DOI":"10.5306\/wjco.v12.i10.897","volume":"12","author":"N Segaran","year":"2021","unstructured":"Segaran N, Devine C, Wang M, Ganeshan D. Current update on imaging for pancreatic neuroendocrine neoplasms. World J Clin Oncol. 2021;12:897\u2013911. https:\/\/doi.org\/10.5306\/wjco.v12.i10.897.","journal-title":"World J Clin Oncol"},{"key":"8039_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13318","volume":"35","author":"J Hofland","year":"2023","unstructured":"Hofland J, Falconi M, Christ E, Castano JP, Faggiano A, Lamarca A, et al. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol. 2023;35:e13318. https:\/\/doi.org\/10.1111\/jne.13318.","journal-title":"J Neuroendocrinol"},{"key":"8039_CR3","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1210\/clinem\/dgab559","volume":"106","author":"KI Kurakawa","year":"2021","unstructured":"Kurakawa KI, Okada A, Manaka K, Konishi T, Jo T, Ono S, et al. Clinical characteristics and incidences of benign and malignant insulinoma using a national inpatient database in Japan. J Clin Endocrinol Metab. 2021;106:3477\u201386. https:\/\/doi.org\/10.1210\/clinem\/dgab559.","journal-title":"J Clin Endocrinol Metab"},{"key":"8039_CR4","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1210\/clinem\/dgad641","volume":"109","author":"J Hofland","year":"2024","unstructured":"Hofland J, Refardt JC, Feelders RA, Christ E, de Herder WW. Approach to the patient: insulinoma. J Clin Endocrinol Metab. 2024;109:1109\u201318. https:\/\/doi.org\/10.1210\/clinem\/dgad641.","journal-title":"J Clin Endocrinol Metab"},{"key":"8039_CR5","doi-asserted-by":"publisher","first-page":"e220321","DOI":"10.1530\/ERC-22-0321","volume":"30","author":"WM Hackeng","year":"2023","unstructured":"Hackeng WM, Brosens LAA, Dreijerink KMA. Aggressive versus indolent insulinomas: new clinicopathological insights. Endocr Relat Cancer. 2023;30:e220321. https:\/\/doi.org\/10.1530\/ERC-22-0321.","journal-title":"Endocr Relat Cancer."},{"key":"8039_CR6","doi-asserted-by":"publisher","first-page":"434","DOI":"10.20524\/aog.2022.0707","volume":"35","author":"E Svensson","year":"2002","unstructured":"Svensson E, Muth A, Hedenstrom P, Ragnarsson O. The incidence of insulinoma in Western Sweden between 2002 and 2019. Ann Gastroenterol. 2002;35:434\u201340. https:\/\/doi.org\/10.20524\/aog.2022.0707.","journal-title":"Ann Gastroenterol"},{"key":"8039_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/MPA.0000000000000718","volume":"46","author":"R Yu","year":"2017","unstructured":"Yu R, Nissen NN, Hendifar A, Tang L, Song YL, Chen YJ, et al. A clinicopathological study of malignant insulinoma in a contemporary series. Pancreas. 2017;46:48\u201356. https:\/\/doi.org\/10.1097\/MPA.0000000000000718.","journal-title":"Pancreas"},{"key":"8039_CR8","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1007\/s00259-025-07288-x","volume":"52","author":"H Yu","year":"2025","unstructured":"Yu H, Bao X, Gu Y, Pan M, He Q, Li D, et al. Comparison of PET\/CT using (68)Ga-NOTA-Exendin-4 with (68)Ga-DOTATATE, (18)F-FDG, and conventional imaging in the localization of insulinomas. Eur J Nucl Med Mol Imaging. 2025;52:4102\u201311. https:\/\/doi.org\/10.1007\/s00259-025-07288-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8039_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2024.111669","volume":"179","author":"MM Abdelkawi","year":"2024","unstructured":"Abdelkawi MM, Romeih MA, Nasr MA, NasrElDin EA. (68)Ga-DOTATATE PET\/CT: how is it reliable in imaging of cases having clinical suspicion of insulinomas? Eur J Radiol. 2024;179:111669. https:\/\/doi.org\/10.1016\/j.ejrad.2024.111669.","journal-title":"Eur J Radiol"},{"key":"8039_CR10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00259-003-1184-3","volume":"30","author":"JC Reubi","year":"2003","unstructured":"Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30:781\u201393. https:\/\/doi.org\/10.1007\/s00259-003-1184-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8039_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/apm.13297","volume":"131","author":"E Peltola","year":"2023","unstructured":"Peltola E, Vesterinen T, Leijon H, Hannula P, Huhtala H, Makinen M, et al. Immunohistochemical somatostatin receptor expression in insulinomas. APMIS. 2023;131:152\u201360. https:\/\/doi.org\/10.1111\/apm.13297.","journal-title":"APMIS"},{"key":"8039_CR12","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2967\/jnumed.110.085142","volume":"52","author":"D Wild","year":"2011","unstructured":"Wild D, Christ E, Caplin ME, Kurzawinski TR, Forrer F, Brandle M, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med. 2011;52:1073\u20138. https:\/\/doi.org\/10.2967\/jnumed.110.085142.","journal-title":"J Nucl Med"},{"key":"8039_CR13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00428-025-04098-2","volume":"486","author":"H Watanabe","year":"2025","unstructured":"Watanabe H, Fujishima F, Yamazaki Y, Imamura M, Hijioka S, Hara K, et al. GLP-1R status using validated monoclonal antibody in 689 cases of neuroendocrine neoplasm and its correlation with somatostatin receptor scintigraphy, insulin production, and histological grades. Virchows Arch. 2025;486:1317\u201326. https:\/\/doi.org\/10.1007\/s00428-025-04098-2.","journal-title":"Virchows Arch"},{"key":"8039_CR14","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1007\/s00259-025-07298-9","volume":"52","author":"H Zhang","year":"2025","unstructured":"Zhang H, Pan Q, Liu S, Feng J, Yu M, Li N, et al. Glucagon-like peptide-1 receptor PET\/CT with (68)Ga-exendin-4 for localizing insulinoma: a real-world, single-center study. Eur J Nucl Med Mol Imaging. 2025;52:4487\u201396. https:\/\/doi.org\/10.1007\/s00259-025-07298-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8039_CR15","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.2967\/jnumed.124.268158","volume":"65","author":"M Boss","year":"2024","unstructured":"Boss M, Eriksson O, Mikkola K, Eek A, Brom M, Buitinga M, et al. Improved localization of insulinomas using (68)Ga-NODAGA-exendin-4 PET\/CT. J Nucl Med. 2024;65:1959\u201364. https:\/\/doi.org\/10.2967\/jnumed.124.268158.","journal-title":"J Nucl Med"},{"key":"8039_CR16","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1210\/jc.2013-3541","volume":"99","author":"O Eriksson","year":"2014","unstructured":"Eriksson O, Velikyan I, Selvaraju RK, Kandeel F, Johansson L, Antoni G, et al. Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report. J Clin Endocrinol Metab. 2014;99:1519\u201324. https:\/\/doi.org\/10.1210\/jc.2013-3541.","journal-title":"J Clin Endocrinol Metab"},{"key":"8039_CR17","doi-asserted-by":"publisher","first-page":"e651","DOI":"10.1097\/RLU.0000000000006008","volume":"50","author":"J Gao","year":"2025","unstructured":"Gao J, Xu J, Liang Y, Chen J, Song S. Evaluation of metastatic insulinoma with severe hypoglycemia using 68Ga-exendin-4 PET\/CT. Clin Nucl Med. 2025;50:e651\u20133. https:\/\/doi.org\/10.1097\/RLU.0000000000006008.","journal-title":"Clin Nucl Med"},{"key":"8039_CR18","doi-asserted-by":"publisher","unstructured":"Ata F, Choudry H, Khan AA, Anum, Khamees I, Al-Sadi A, et al. A systematic review of literature on Insulin-like growth factor-2-mediated hypoglycaemia in non-islet cell tumours. Endocrinol Diabetes Metab. 2024;7:e00471. https:\/\/doi.org\/10.1002\/edm2.471.","DOI":"10.1002\/edm2.471"},{"key":"8039_CR19","doi-asserted-by":"publisher","first-page":"736","DOI":"10.2967\/jnumed.106.038679","volume":"48","author":"M Korner","year":"2007","unstructured":"Korner M, Stockli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007;48:736\u201343. https:\/\/doi.org\/10.2967\/jnumed.106.038679.","journal-title":"J Nucl Med"},{"key":"8039_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015164","author":"T Vesterinen","year":"2023","unstructured":"Vesterinen T, Peltola E, Leijon H, Hannula P, Huhtala H, Makinen MJ, et al. Immunohistochemical glucagon-like peptide-1 receptor expression in human insulinomas. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms242015164.","journal-title":"Int J Mol Sci"},{"key":"8039_CR21","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1210\/jc.2012-1230","volume":"97","author":"RV Thakker","year":"2012","unstructured":"Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97:2990\u20133011. https:\/\/doi.org\/10.1210\/jc.2012-1230.","journal-title":"J Clin Endocrinol Metab"},{"key":"8039_CR22","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1159\/000538285","volume":"114","author":"J Xu","year":"2024","unstructured":"Xu J, Xu X, Zhang M, Liu W, Chen J, Song S. Heterogeneity of multiple pancreatic neuroendocrine tumors identified by 68Ga-DOTANOC and 68Ga-exendin-4 PET\/CT in a patient with endogenous hyperinsulinemic hypoglycemia and multiple endocrine neoplasia 1. Neuroendocrinology. 2024;114:866\u201371. https:\/\/doi.org\/10.1159\/000538285.","journal-title":"Neuroendocrinology"},{"key":"8039_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1055\/a-2694-8248","volume":"64","author":"KS Ambulkar","year":"2025","unstructured":"Ambulkar KS, Shah R, Lila A, Sharma A, Barnabas R, Karlekar M, et al. Outcomes of 68Ga-NODAGA-exendin-4 PET\/CT guided surgical management of insulinomas in MEN1: a preliminary study. Nuklearmedizin. 2025;64:301\u20137. https:\/\/doi.org\/10.1055\/a-2694-8248.","journal-title":"Nuklearmedizin"},{"key":"8039_CR24","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1007\/s00259-023-06182-8","volume":"50","author":"W Guo","year":"2023","unstructured":"Guo W, Chen Y, He X, Fu H, Huang J, Chen H. [(68) Ga]Ga-DOTATATE PET\/CT versus [(68) Ga]Ga-Exendin-4 PET\/CT in the evaluation of metastatic insulinoma. Eur J Nucl Med Mol Imaging. 2023;50:2910\u20131. https:\/\/doi.org\/10.1007\/s00259-023-06182-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8039_CR25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1210\/jc.2015-2436","volume":"101","author":"J Crona","year":"2016","unstructured":"Crona J, Norlen O, Antonodimitrakis P, Welin S, Stalberg P, Eriksson B. Multiple and secondary hormone secretion in patients with metastatic pancreatic neuroendocrine tumours. J Clin Endocrinol Metab. 2016;101:445\u201352. https:\/\/doi.org\/10.1210\/jc.2015-2436.","journal-title":"J Clin Endocrinol Metab"},{"key":"8039_CR26","doi-asserted-by":"publisher","first-page":"682","DOI":"10.7326\/M14-2132","volume":"162","author":"L de Mestier","year":"2015","unstructured":"de Mestier L, Hentic O, Cros J, Walter T, Roquin G, Brixi H, et al. Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study. Ann Intern Med. 2015;162:682\u20139. https:\/\/doi.org\/10.7326\/M14-2132.","journal-title":"Ann Intern Med"},{"key":"8039_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1210\/clinem\/dgaf253","volume":"111","author":"T Murakami","year":"2025","unstructured":"Murakami T, Yoshida H, Sakaki K, Otani D, Kawai Miyake K, Shimizu Y, et al. Qualitative and quantitative analyses of noninvasive diagnosis of insulinoma using [18F]FB(ePEG12)12-Exendin-4 PET\/CT. J Clin Endocrinol Metab. 2025;111:209\u201317. https:\/\/doi.org\/10.1210\/clinem\/dgaf253.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08039-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08039-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08039-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:32:05Z","timestamp":1790929925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08039-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8039"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08039-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"23 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was granted by the Ethics Committee of Fudan University Shanghai Cancer Center in line with the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants enrolled in the study. This article does not contain any private patient information.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}